Does the media prefer AMLX or IONS?

In the previous week, Amylyx Pharmaceuticals had 24 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 18 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat Amylyx Pharmaceuticals' score of 0.71 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 14 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMLX or CYTK?

In the previous week, Amylyx Pharmaceuticals had 34 more articles in the media than Cytokinetics. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 8 mentions for Cytokinetics. Amylyx Pharmaceuticals' average media sentiment score of 0.71 beat Cytokinetics' score of 0.65 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 14 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SYRE or AMLX more profitable?

Spyre Therapeutics' return on equity of -30.74% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media favor SYRE or AMLX?

In the previous week, Amylyx Pharmaceuticals had 37 more articles in the media than Spyre Therapeutics. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 5 mentions for Spyre Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 0.71 beat Spyre Therapeutics' score of 0.43 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amylyx Pharmaceuticals 14 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is PCVX or AMLX more profitable?

Vaxcyte's return on equity of -37.56% beat Amylyx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -37.56% -33.62% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media favor PCVX or AMLX?

In the previous week, Amylyx Pharmaceuticals had 38 more articles in the media than Vaxcyte. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.07 beat Amylyx Pharmaceuticals' score of 0.71 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 14 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMVT or AMLX more profitable?

Amylyx Pharmaceuticals' return on equity of -52.92% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Amylyx Pharmaceuticals N/A -52.92% -48.53%

Does the media favor IMVT or AMLX?

In the previous week, Amylyx Pharmaceuticals had 34 more articles in the media than Immunovant. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 8 mentions for Immunovant. Immunovant's average media sentiment score of 0.97 beat Amylyx Pharmaceuticals' score of 0.71 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 14 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Amylyx Pharmaceuticals (AMLX) Competitors

$38.66 -1.00 (-2.52%)

As of 08/21/2026 04:00 PM Eastern

Compare

AMLX vs. IONS, CYTK, SYRE, PCVX, and IMVT

Should you buy Amylyx Pharmaceuticals stock or one of its competitors? Amylyx Pharmaceuticals's main competitors and comparable companies include Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), Spyre Therapeutics (SYRE), Vaxcyte (PCVX), and Immunovant (IMVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Amylyx Pharmaceuticals compare to Ionis Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Amylyx Pharmaceuticals currently has a consensus target price of $36.25, indicating a potential downside of 6.23%. Ionis Pharmaceuticals has a consensus target price of $94.15, indicating a potential upside of 57.60%. Given Ionis Pharmaceuticals' higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Amylyx Pharmaceuticals has higher earnings, but lower revenue than Ionis Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	49.30	-$144.74M	-$1.43	N/A
Ionis Pharmaceuticals	$944M	10.52	-$381.39M	-$3.46	N/A

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Amylyx Pharmaceuticals' return on equity of -52.92% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Amylyx Pharmaceuticals had 24 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 18 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.08 beat Amylyx Pharmaceuticals' score of 0.71 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	14 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amylyx Pharmaceuticals has a beta of -0.21, indicating that its stock price is 121% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Summary

Amylyx Pharmaceuticals beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Cytokinetics?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Cytokinetics	-1,321.12%	N/A	-51.01%

Amylyx Pharmaceuticals currently has a consensus target price of $36.25, suggesting a potential downside of 6.23%. Cytokinetics has a consensus target price of $102.20, suggesting a potential upside of 33.00%. Given Cytokinetics' higher probable upside, analysts plainly believe Cytokinetics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86

Amylyx Pharmaceuticals has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Amylyx Pharmaceuticals has higher earnings, but lower revenue than Cytokinetics. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	49.30	-$144.74M	-$1.43	N/A
Cytokinetics	$88.04M	108.60	-$784.96M	-$7.22	N/A

In the previous week, Amylyx Pharmaceuticals had 34 more articles in the media than Cytokinetics. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 8 mentions for Cytokinetics. Amylyx Pharmaceuticals' average media sentiment score of 0.71 beat Cytokinetics' score of 0.65 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	14 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amylyx Pharmaceuticals beats Cytokinetics on 10 of the 17 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Spyre Therapeutics has a beta of 3.03, meaning that its stock price is 203% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.21, meaning that its stock price is 121% less volatile than the broader market.

Amylyx Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	10,522.17	-$155.20M	-$1.95	N/A
Amylyx Pharmaceuticals	$87.37M	49.30	-$144.74M	-$1.43	N/A

In the previous week, Amylyx Pharmaceuticals had 37 more articles in the media than Spyre Therapeutics. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 5 mentions for Spyre Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 0.71 beat Spyre Therapeutics' score of 0.43 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	14 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Spyre Therapeutics' return on equity of -30.74% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Spyre Therapeutics presently has a consensus price target of $111.69, indicating a potential upside of 4.89%. Amylyx Pharmaceuticals has a consensus price target of $36.25, indicating a potential downside of 6.23%. Given Spyre Therapeutics' higher possible upside, analysts clearly believe Spyre Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Amylyx Pharmaceuticals beats Spyre Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vaxcyte has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.21, meaning that its stock price is 121% less volatile than the broader market.

In the previous week, Amylyx Pharmaceuticals had 38 more articles in the media than Vaxcyte. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 4 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.07 beat Amylyx Pharmaceuticals' score of 0.71 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	14 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte currently has a consensus target price of $86.00, indicating a potential upside of 37.34%. Amylyx Pharmaceuticals has a consensus target price of $36.25, indicating a potential downside of 6.23%. Given Vaxcyte's higher probable upside, equities analysts plainly believe Vaxcyte is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Vaxcyte's return on equity of -37.56% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Amylyx Pharmaceuticals has higher revenue and earnings than Vaxcyte. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Amylyx Pharmaceuticals	$87.37M	49.30	-$144.74M	-$1.43	N/A

Summary

Amylyx Pharmaceuticals beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Amylyx Pharmaceuticals compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Amylyx Pharmaceuticals' return on equity of -52.92% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%

Amylyx Pharmaceuticals has higher revenue and earnings than Immunovant. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Amylyx Pharmaceuticals	$87.37M	49.30	-$144.74M	-$1.43	N/A

In the previous week, Amylyx Pharmaceuticals had 34 more articles in the media than Immunovant. MarketBeat recorded 42 mentions for Amylyx Pharmaceuticals and 8 mentions for Immunovant. Immunovant's average media sentiment score of 0.97 beat Amylyx Pharmaceuticals' score of 0.71 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	14 Very Positive mention(s)	7 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

47.1% of Immunovant shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 1.9% of Immunovant shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Immunovant has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market.

Immunovant currently has a consensus price target of $44.00, indicating a potential downside of 0.83%. Amylyx Pharmaceuticals has a consensus price target of $36.25, indicating a potential downside of 6.23%. Given Immunovant's higher probable upside, equities analysts plainly believe Immunovant is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Amylyx Pharmaceuticals beats Immunovant on 11 of the 15 factors compared between the two stocks.

Get Amylyx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMLX vs. The Competition

Export

Metric	Amylyx Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.31B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-27.03	11.62	272.60	24.25
Price / Sales	49.30	1,338.15	618.96	99.05
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	17.98	16.80	13.05	6.20
Net Income	-$144.74M	-$12.50M	$3.47B	$348.59M
7 Day Performance	78.73%	3.29%	2.09%	0.08%
1 Month Performance	119.78%	8.23%	6.64%	3.88%
1 Year Performance	315.70%	55.05%	25.02%	16.98%

Amylyx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMLX Amylyx Pharmaceuticals	1.7938 of 5 stars	$38.66 -2.5%	$36.25 -6.2%	+315.7%	$4.31B	$87.37M	N/A	200	Trending News Analyst Forecast Analyst Revision
IONS Ionis Pharmaceuticals	3.5655 of 5 stars	$58.63 +2.4%	$94.65 +61.4%	+39.9%	$9.51B	$944M	N/A	1,402	News Coverage Positive News Analyst Upgrade Options Volume
CYTK Cytokinetics	3.3778 of 5 stars	$75.87 +2.3%	$102.20 +34.7%	+100.4%	$9.22B	$88.04M	N/A	250	Insider Trade
SYRE Spyre Therapeutics	1.4993 of 5 stars	$104.60 +0.9%	$111.69 +6.8%	+512.7%	$9.11B	$890K	N/A	73
PCVX Vaxcyte	1.9709 of 5 stars	$60.22 +3.7%	$86.00 +42.8%	+93.9%	$8.64B	N/A	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMLX) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. IONS, CYTK, SYRE, PCVX, and IMVT

How does Amylyx Pharmaceuticals compare to Ionis Pharmaceuticals?

Summary

How does Amylyx Pharmaceuticals compare to Cytokinetics?

Summary

How does Amylyx Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Amylyx Pharmaceuticals compare to Vaxcyte?

Summary

How does Amylyx Pharmaceuticals compare to Immunovant?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amylyx Pharmaceuticals (AMLX) Competitors

AMLX vs. IONS, CYTK, SYRE, PCVX, and IMVT

How does Amylyx Pharmaceuticals compare to Ionis Pharmaceuticals?

Do analysts recommend AMLX or IONS?

Which has preferable valuation & earnings, AMLX or IONS?

Is AMLX or IONS more profitable?

Do institutionals and insiders believe in AMLX or IONS?

Does the media prefer AMLX or IONS?

Which has more risk & volatility, AMLX or IONS?

Summary

How does Amylyx Pharmaceuticals compare to Cytokinetics?

Do institutionals and insiders have more ownership in AMLX or CYTK?

Is AMLX or CYTK more profitable?

Do analysts rate AMLX or CYTK?

Which has more volatility and risk, AMLX or CYTK?

Which has better valuation and earnings, AMLX or CYTK?

Does the media prefer AMLX or CYTK?

Summary

How does Amylyx Pharmaceuticals compare to Spyre Therapeutics?

Which has more risk & volatility, SYRE or AMLX?

Which has better earnings and valuation, SYRE or AMLX?

Does the media favor SYRE or AMLX?

Do institutionals and insiders believe in SYRE or AMLX?

Is SYRE or AMLX more profitable?

Do analysts recommend SYRE or AMLX?

Summary

How does Amylyx Pharmaceuticals compare to Vaxcyte?

Do institutionals & insiders believe in PCVX or AMLX?

Which has more volatility & risk, PCVX or AMLX?

Does the media favor PCVX or AMLX?

Do analysts prefer PCVX or AMLX?

Is PCVX or AMLX more profitable?

Which has higher earnings & valuation, PCVX or AMLX?

Summary

How does Amylyx Pharmaceuticals compare to Immunovant?

Is IMVT or AMLX more profitable?

Which has higher earnings and valuation, IMVT or AMLX?

Does the media favor IMVT or AMLX?

Do insiders & institutionals believe in IMVT or AMLX?

Which has more volatility & risk, IMVT or AMLX?

Do analysts rate IMVT or AMLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMLX vs. The Competition

Amylyx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools